Aims: Navoximod (GDC-0919, NLG-919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1 (IDO1), developed to treat the acquired immune tolerance associated with cancer. The primary objectives of this study were to assess navoximod's absolute bioavailability (aBA), determine the mass balance and routes of elimination of [ Results: The aBA of navoximod was estimated to be 55.5%, with a geometric mean (%CV) plasma clearance and volume of distribution of 62.0 L/h (21.0%) and 1120 L (28.4%), respectively. Mean recovery of total radioactivity was 87.8%, with 80.4% detected in urine and the remainder (7.4%) in faeces. Navoximod was extensively metabolized, with unchanged navoximod representing 5.45% of the dose recovered in the urine and faeces. Glucuronidation was identified as the primary route of metabolism, with the major glucuronide metabolite, M28, accounting for 57.5% of the total drug-derived exposure and 59.7% of the administered dose recovered in urine.
Indoleamine-2,3-dioxygenase 1 (IDO1, EC 1.13.11.52) is a cytosolic enzyme that catalyses the oxidation of the essential amino acid, L-tryptophan, into kynurenine. 1 The IDO1 pathway plays an important role in the local control of inflammation and acquired immune peripheral tolerance. [1] [2] [3] IDO1 is expressed in tumour and host immune cells in patients with various tumour types and its expression level is associated with significantly worse clinical outcomes. [4] [5] [6] [7] [8] Given the important role of IDO1 in immune tolerance and overexpression in many human cancers, it is a prime target for cancer immunotherapy.
Navoximod (also known as GDC-0919 and NLG-919) is a potent and selective small-molecule inhibitor of IDO1 and an investigational drug candidate for the treatment of local and peripheral immune tolerance that might arise in association with cancer. Nonclinical pharmacology studies indicated that navoximod inhibits IDO1 with a potency of 75-90 nM in cell-based assays. 9 In preclinical models, navoximod in combination with anti-PD-L1 (programmed death-ligand 1), enhances the activity of intratumoral CD8+ T cells and inhibits tumour growth compared to either treatment alone. 10 Clinically, navoximod has favourable safety, tolerability and pharmacokinetic profiles when given as a monotherapy or in combination with atezolizumab, a PD-L1 inhibitor. 11, 12 Navoximod is rapidly The objectives of the current study were to determine the absolute bioavailability, characterize the pharmacokinetics of navoximod following oral and IV administration, determine the mass balance and routes of excretion of navoximod, and characterize the metabolites of navoximod in plasma, urine and faeces. Overall, the data from this study provided a comprehensive understanding of the disposition of navoximod in humans, which was applied to interpret its oral bioavailability and total metabolism. was based on subjects meeting the discharge criteria that blood and plasma radioactivity levels were below the limit of quantitation for two consecutive samples and ≥90% of the dose had been recovered; or total radioactivity in excreta reached ≤1% of the administered dose for two consecutive collections.
| Subjects
Healthy volunteers that were eligible for inclusion in this study were What this study adds
• The study provided definitive information regarding the absolute bioavailability and the metabolism, elimination and clearance pathways of navoximod.
• Identification of glucuronidation as the major metabolic pathway of navoximod and M28 as the major circulating metabolite.
infection within 4 weeks; prior exposure to immune-modulating oncology therapeutics; use of prescription medications/products within 14 days; use of non-prescription medications/products within 7 days; participation in a previous radiolabel study within 12 months (Part 2 only); exposure to significant radiation within 12 months (Part 2 only).
The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All participants provided written informed consent prior to any study-related procedures. The clinical study protocol, informed consent forms, and any information given to the subjects and relevant supporting information were submitted for review and approval by the institutional review board (IRB) of Covance prior to study screening.
| Dose rationale
Single and twice daily oral doses (up to the maximum assessed dose of Given the short half-life of navoximod (~12 hours), a radioactivity dose of 600 μCi for the AME portion of this study was selected to ensure there was sufficient radioactivity in circulation for metabolite profiling using conventional radio-detection methods. The radiation burden of a single 600 μCi oral dose of 14 C-navoximod was estimated to be 0.56% of the 3000-5000 mrem limits specified by the United
States Code of Federal Regulations (CFR) based on dosimetry calculations from tissue distribution data obtained in rats. analysis. In addition, the IV and oral solution appearances were clear and colourless prior to dosing.
| Safety assessments

| Sample collection
In Part 1 of the study, blood samples for plasma concentrations of navoximod were collected from subjects at pre-dose, end of IV push respectively. The intra-run and inter-run precision of both assays was within 7.2% and accuracy was within ±12.2% of the nominal concentration values. Navoximod was found to be stable in human plasma over five freeze-thaw cycles, at least for 110 days at −10°C to −30°C and −60°C to −80°C, and for 24 h at room temperature. Chromatographic separations were performed using an UltiMate 3000 UPLC system (Thermo Scientific, San Jose, CA) using a Kinetex Radiochromatograms were reconstructed using Laura Evaluation software (LabLogic, Brandon, FL) and the radiopeaks were integrated to determine the percent distribution of radioactivity in each sample. 
| Determination of radioactivity
| Metabolite structure identification
| Pharmacokinetic analyses
Mean plasma concentration-time profiles and total radioactivity for plasma, whole blood, urine and faeces data were plotted using GraphPad Prism Version 7.04. PK parameters for unlabelled navoximod in plasma, and total radioactivity in plasma and whole blood were determined by standard non-compartmental methods, 
| Statistics
The sample size of Part 1 (aBA) was selected to minimize exposure of navoximod to healthy volunteers, but was adequate to characterize the safety, tolerability and pharmacokinetics of navoximod (not based on formal sample size calculations). For Part 2 (hAME), the sample size was based on practical considerations needed to meet the objectives of an ADME study, 13 and was not powered on the basis of statistical hypothesis testing.
No formal statistical analyses were performed in this study.
Plasma, blood, urine and faecal concentration, and radioactivity-time curves are presented as mean and standard deviation. PK parameters are summarized by descriptive statistics. Dose-normalized geometric mean ratios and 90% confidence intervals (CIs) were computed for PK parameters for oral versus IV dosing to estimate absolute bioavailability.
| Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMA-COLOGY, 14 and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18. 
| Part 2: Mass balance
The single mass dose of Pharmacokinetic parameters for unlabelled navoximod and total radioactivity in plasma and whole blood are summarized in Table 2 ; and 4.21%, respectively, of plasma total radioactivity, suggesting the presence of circulating metabolites.
The blood-to-plasma ratio was determined from the total radioactivity, which included both parent and metabolites. The geometric mean whole blood to plasma AUC 0-∞ ratio for total radioactivity was 0.965. Blood-to-plasma ratios increased from 0.5 to 1.6 over the duration of the study, indicating slightly higher association of [ 14 C]-radioactivity towards blood cells with time. Since the half-life of total radioactivity is more than 10 times longer than the half-life of navoximod, the changes of the blood-to-plasma ratio over time is likely related to metabolites rather than navoximod.
Cumulative recovery of total radioactivity in urine and faeces following administration of [ 14 C]-navoximod is presented in Figure 3 .
The mean total recovery of the radioactive dose in excreta up to 336 h post dose was 87.8%, with 85.0% of the total radioactivity recovered within the first 72 h. The majority of the total radioactivity was eliminated in the urine, with mean ± SD recoveries of 80.4% ± 5.53% and 7.44% ± 3.82% in the urine and faeces, respectively.
| Extraction recovery of metabolite profiling samples
The extraction recoveries of the radioactivity from plasma samples decreased over time, with 95.0% of the radioactivity extracted from the 0.5-hour post-dose plasma sample and 52.5% of the radioactivity extracted from the 48-hour post-dose plasma sample. The majority of the circulating radioactivity at ≥72 hours post-dose was not extractable (extraction recoveries were 27-38%). The extraction recoveries of the AUC 0-48 hour pooled plasma samples among the eight subjects were 76.1-86.5%. The plasma samples were extracted multiple times until the radioactivity in the supernatant was below the detection limit of the liquid scintillation counter. Therefore, the unextracted radioactivity was presumed to be tightly associated with plasma proteins. The extraction recoveries of faecal homogenate were 83.3-109% (n = 8).
| Navoximod metabolite profiling and identification
Representative HPLC radiochromatograms of pooled 0-48 h plasma, plasma at 72 h and 120 h, pooled urine and pooled faeces are presented in Figure S1 . The protonated molecular ion [M + H] + and major product ions observed by high resolution full scan and MS 2 experiments for navoximod and its metabolites are listed in Table S1 . The discussion of MS/MS fragment interpretation of navoximod and its metabolites is also provided in the supplemental information.
The relative abundances and exposures of navoximod and its metabolites in plasma, and their percentage of dose detected in urine and faeces are provided in Table 3 . The proposed biotransformation pathways are presented in Figure 4 . In the pooled 0-48 h plasma, Mean values from AUC 0-48 hour of pooled plasma (n = 8) adjusted with extraction recovery. The unextracted radioactivity accounted for 20.4% of the total radioactivity in the plasma sample.
b Mean values from eight subjects.
Only 7.44% of the administered radioactivity was recovered in faeces, indicating that faecal excretion was a minor route of elimination for navoximod-related radioactivity. The metabolite profiles from the pooled faeces were similar among the eight subjects. Unchanged navoximod represented 3.79% of the dose. M17 (oxidation, +34 Da) accounted for 1.54% of the dose. All other metabolites in faeces represented less than 1% of the administered dose.
| Safety and tolerability
All IV and oral doses in both parts of the study were generally well tolerated and all adverse events were mild in severity. There were no clinically significant changes in laboratory test parameters or in blood pressure, pulse rate, electrocardiographic or physical examination findings.
| DISCUSSION
This study investigated the absolute bioavailability of navoximod, determined the mass balance and routes of elimination of [ The disposition of navoximod and its metabolites following a single oral dose of 200 mg navoximod to healthy volunteers is presented in Figure 5 . The fraction of the dose absorbed (F a ) was estimated to be 0.841 using the sum of radioactivity recovered in urine (80.4%) and radioactivity in faeces that was characterized as metabolites (3.65%). In conclusion, this study determined the absolute bioavailability, mass balance, elimination routes, and metabolite profiling and characterization of navoximod in healthy subjects. Navoximod was well tolerated and showed moderate oral bioavailability. Navoximod was quickly absorbed and extensively metabolized. The major metabolic pathway of navoximod was glucuronidation.
